AlzeCure Out‑Licenses Preclinical Alzheimer’s Candidate ACD680 to Eli Lilly
The deal gives Lilly global development and commercial rights with a $10 million upfront payment plus milestone terms that could push value above $1 billion pending Swedish foreign investment clearance.
Overview
- AlzeCure announced the out‑licensing agreement with Eli Lilly on Tuesday, June 9, 2026, and the news sent AlzeCure shares up more than 301 percent on heavy trading.
- Under the pact Lilly receives worldwide rights to ACD680, a compound still in preclinical testing, and AlzeCure will get a $10 million upfront payment with additional development and commercial milestone payments and tiered mid‑single digit royalties.
- ACD680 is a small‑molecule gamma‑secretase modulator designed to lower production of the toxic amyloid‑beta 42 peptide and raise levels of shorter, non‑toxic amyloid variants Aβ37 and Aβ38, a mechanism AlzeCure says has strong genetic rationale.
- The transaction remains subject to Swedish foreign direct investment approval before it can close, so clinical development risk and regulatory steps still determine whether milestones and royalties will be earned.
- The deal gives AlzeCure near‑term funding and external validation while fitting Lilly’s broader Alzheimer’s strategy, but observers note the gamma‑secretase modulator approach has a mixed development history and clinical proof will be required for long‑term upside.